Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E19.64 EPS (ttm)2.88 Insider Own0.20% Shs Outstand1.66B Perf Week4.00%
Market Cap94.14B Forward P/E18.02 EPS next Y3.14 Insider Trans-5.04% Shs Float1.65B Perf Month5.24%
Income4.84B PEG2.14 EPS next Q0.73 Inst Own71.30% Short Float1.13% Perf Quarter1.34%
Sales19.97B P/S4.72 EPS this Y184.60% Inst Trans-1.86% Short Ratio2.24 Perf Half Y-3.49%
Book/sh8.67 P/B6.53 EPS next Y6.72% ROA14.50% Target Price57.18 Perf Year-22.03%
Cash/sh3.68 P/C15.41 EPS next 5Y9.19% ROE31.60% 52W Range46.01 - 77.12 Perf YTD-3.08%
Dividend1.56 P/FCF188.27 EPS past 5Y4.20% ROI20.00% 52W High-26.56% Beta1.17
Dividend %2.75% Quick Ratio1.40 Sales past 5Y-1.80% Gross Margin74.30% 52W Low23.10% ATR1.00
Employees25000 Current Ratio1.60 Sales Q/Q12.30% Oper. Margin31.60% RSI (14)64.23 Volatility2.24% 1.81%
OptionableYes Debt/Eq0.59 EPS Q/Q32.40% Profit Margin24.20% Rel Volume2.49 Prev Close57.33
ShortableYes LT Debt/Eq0.50 EarningsJul 27 BMO Payout52.80% Avg Volume8.32M Price56.64
Recom2.40 SMA204.40% SMA504.24% SMA2003.57% Volume20,761,182 Change-1.20%
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Jun-23-17 09:00PM  On Not Talking About the 'Market'; Darth Vader, Meet Amazon: Jim Cramer's Best Blog
Jun-22-17 07:36AM  Changes in Bristol-Myers Squibbs Profitability 1Q17 Market Realist
Jun-21-17 10:37AM  Bristol-Myers Squibb Reported Revenue Growth in 1Q17 Market Realist
10:00AM  S&P 500 Buybacks Fall 17.5% Year-over-Year to $133.1 Billion for Q1 2017 PR Newswire
09:08AM  Analyzing Bristol-Myers Squibbs Valuation on June 20 Market Realist
07:36AM  Adcetris-Opdivo Combination for Classical Hodgkin Lymphoma Market Realist
07:00AM  U.S. Supreme Court ruling threatens massive talc litigation against J&J Reuters
06:59AM  Bristol-Myers Squibb Announces the Expiration of its Cash Tender Offer Business Wire
Jun-20-17 09:45PM  U.S. Supreme Court ruling threatens massive talc litigation against J&J Reuters
07:13PM  U.S. Supreme Court ruling threatens massive talc litigation against J&J Reuters
06:05PM  Why Pomalyst Could See Significant Revenue Growth in 2017 Market Realist
03:40PM  Bristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Any and All of Certain of its Outstanding Debt Securities Business Wire
03:36PM  Updates on the Adcetris and Opdivo Combination Market Realist
02:06PM  Data from the Checkmate-205 Study Evaluating Opdivo Market Realist
12:15PM  Bristol-Myers Squibb Is Poised for a Breakout
12:09PM  SK Biotek to Acquire Manufacturing Facility in Swords, Ireland Market Realist
07:27AM  5 Most Profitable Big Pharma Stocks on the Market Right Now Motley Fool
06:00AM  Top 10 Holdings of Our Ultimate Stock-Pickers' Index Morningstar
Jun-19-17 06:11PM  U.S. Supreme Court again limits where companies can be sued Reuters
06:10PM  U.S. Supreme Court again limits where companies can be sued Reuters
10:56AM  High court sides with drugmaker in Plavix lawsuit Associated Press
10:52AM  Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205 Zacks
10:49AM  U.S. Supreme Court limits where companies can be sued Reuters
10:12AM  Companies Get New Suit Limits as Supreme Court Backs Bristol-Myers Bloomberg
08:15AM  Corporate News Blog - Bristol-Myers Squibb Announces Sale of Swords Plant; Set to Expand its Biologics Portfolio Accesswire
04:42AM  Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon
Jun-16-17 06:58AM  Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response in Adult Patients with Relapsed or Progressed Classical Hodgkin Lymphoma Business Wire
04:35AM  Bristol-Myers Squibb to Sell Manufacturing Facility in Swords, Ireland to SK Biotek Co., Ltd. Business Wire
Jun-15-17 03:21PM  Is the Market Wrong About Bristol-Myers Squibb? Motley Fool
01:19PM  ETFs with exposure to Bristol-Myers Squibb Co. : June 15, 2017 Capital Cube
06:58AM  Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed Hodgkin Lymphoma at the International Conference on Malignant Lymphoma Business Wire
Jun-14-17 01:59PM  Bristol-Myers Squibb Co. Value Analysis (NYSE:BMY) : June 14, 2017 Capital Cube
08:40AM  Bristol-Myers Squibb Announces Cash Tender Offer For Any and All of Certain of Its Outstanding Debt Securities Business Wire
06:59AM  Bristol-Myers Squibb To Present New Research Related to the Treatment of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease at the Annual European Congress of Rheumatology (EULAR 2017) Business Wire
Jun-13-17 05:32PM  Exelixis Initiates Cabozantinib-Tecentriq Combination Trial Zacks
04:05PM  Bristol-Myers Squibb Announces Dividend Business Wire
11:51AM  Will Bristol-Myers Share Merck's Woe?
09:18AM  Merck: A Speed Bump For Keytruda?
08:27AM  Bristol-Myers Squibb Co. breached its 50 day moving average in a Bullish Manner : BMY-US : June 13, 2017 Capital Cube
Jun-12-17 10:00AM  Bristol-Myers Squibb to Announce Results for Second Quarter 2017 on July 27 Business Wire
Jun-09-17 11:09AM  3 Dividend Stocks for Shrewd Investors Motley Fool
05:00AM  Cancer Setback Leaves Bristol-Myers Vulnerable to Takeover Bloomberg
Jun-08-17 07:30AM  Bristol-Myers Squibb Announces Availability of New ORENCIA® (abatacept) Subcutaneous Administration Option for Patients 2 Years of Age and Older with Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA) Business Wire
Jun-07-17 12:56PM  ASCO Was A Bust For Biotech
06:59AM  Bristol-Myers Squibb to Take Part in Goldman Sachs 38th Annual Global Healthcare Conference Business Wire
Jun-06-17 06:17PM  Bristol Myers, Novartis to Explore Potential Treatment for Metastatic Colorectal Cancer
06:12PM  Novartis, Bristol-Myers Collaborate for Opdivo Combination Zacks
09:09AM  Incyte Provides Updated Data on Cancer Combination Therapies Zacks
07:25AM  [$$] Is Bristol-Myers Falling Behind?
Jun-05-17 07:44PM  [$$] F-Star Strikes Drug Deal With Merck KGaA Valued as Much as $1.1 Billion The Wall Street Journal
04:29PM  Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo Zacks
04:05PM  Bristol-Myers Squibb Announces New Collaboration to Evaluate Combination Therapy in Colorectal Cancer Business Wire
01:59PM  Bristol-Myers Squibb: Value Or Value Trap?
11:29AM  Incyte Announces Data on Enzyme Inhibitor with Keytruda Zacks
10:33AM  Bristol-Myers Squibb CEO: Critical that treatments reach ... CNBC Videos
10:28AM  QIAGEN & Bristol-Myers Squibb Partner on Cancer Research Zacks
08:47AM  Here's the Best Dividend Stock in Big Pharma Motley Fool
07:30AM  Encouraging Disease Control Rates Observed with Nivolumab Alone or in Combination with Ipilimumab in Refractory or Relapsing Malignant Pleural Mesothelioma Patients: Results from IFCT-1501 MAPS-2 Trial Business Wire
07:30AM  Clinical Trial Data for Combination of Epacadostat and Opdivo® (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer Business Wire
07:21AM  3 Dividend Stocks Perfect for Retirement Motley Fool
07:15AM  Early, Durable Responses Seen with Sprycel (dasatinib) in First- and Second-Line Treatment of Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Business Wire
12:13AM  [$$] Plenty Can Go Right for Bristol-Myers The Wall Street Journal
Jun-04-17 08:30AM  New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in Resected High-Risk Melanoma Patients Presented at ASCO Business Wire
08:00AM  First Presentation of Efficacy Data from CheckMate -204 Evaluating the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) Demonstrates Anti-tumor Activity in Advanced Melanoma Patients with Brain Metastases Business Wire
Jun-03-17 01:00PM  Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies Business Wire
09:00AM  Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrated Promising Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer in Phase 2 CheckMate -142 Study Business Wire
08:00AM  Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy Business Wire
Jun-02-17 05:00PM  European Commission Approves Bristol-Myers Squibbs Opdivo (nivolumab) for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platinum-Containing Therapy Business Wire
04:18PM  Dow's Merck Beats Out Rival Bristol In Melanoma Study Investor's Business Daily
04:10PM  Bristol Drug Shows Promise In Treatment Of Cervical Cancer Investor's Business Daily
12:49PM  Stocks to watch during ASCO CNBC Videos
11:35AM  [$$] Plenty Can Go Right for Bristol-Myers The Wall Street Journal
08:43AM  Bristol-Myers Squibb Co. breached its 50 day moving average in a Bullish Manner : BMY-US : June 2, 2017 Capital Cube
08:12AM  Pharma Stock Roundup: Positive Data from Lilly & Teva, BMY's Deals & More Zacks
07:49AM  Merck reports positive results for late-stage trial comparing its Keytruda against Bristol-Myers' Yervoy MarketWatch
07:18AM  Bristol-Myers Squibb reports data from phase 1/2 trial for cancers associated with HPV MarketWatch
06:59AM  Opdivo (nivolumab) Data in Patients with Advanced Cervical, Vaginal and Vulvar Cancers from Phase 1/2 CheckMate -358 Presented at ASCO Business Wire
06:56AM  Cancer drug prices could double or triple thanks to this popular but unproven drug trend MarketWatch
06:00AM  Bristol-Myers Squibb and Seattle Genetics Expand Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and ADCETRIS® (Brentuximab Vedotin) in Pivotal Phase 3 Clinical Trial in Relapsed Hodgkin Lymphoma Business Wire
Jun-01-17 08:15AM  Blog Coverage: Array BioPharma and Bristol-Myers Squibb Partner to Investigate Combinations of Binimetinib, Opdivo, and Yervoy in Colorectal Cancer Patients Accesswire
07:01AM  Why Is Bristol-Myers (BMY) Down 3.1% Since the Last Earnings Report? Zacks
May-31-17 11:44AM  Novartis CEO sees no need for big takeover Reuters
11:13AM  Bristol-Myers Partners Array to Investigate Cancer Candidate Zacks
May-30-17 06:20PM  Bristol-Myers Hookup Boosts Array BioPharma
04:14PM  Array BioPharma, Bristol-Myers Squibb to collaborate on cancer drug research American City Business Journals
10:17AM  U.S. top court tightens rules on where companies can be sued Reuters
09:29AM  Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration
06:59AM  Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration PR Newswire
06:59AM  Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo (nivolumab) in Metastatic Cervical Cancer Business Wire
05:17AM  How Two Biotechs Fell On Cancer Partnerships With Bristol-Myers Investor's Business Daily
May-28-17 07:27AM  Better Buy: Celgene Corporation vs. Bristol-Myers Squibb Motley Fool
May-26-17 09:47AM  CORRECTING and REPLACING Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights Business Wire
09:42AM  Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer Zacks
08:08AM  Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data Zacks
07:36AM  Nplate and Vectibix Could Contribute to Amgens Revenue Growth in 2017 Market Realist
May-25-17 10:42AM  Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer Zacks
07:55AM  Getting Struck Twice: Acquisitions And Spinouts In Biotech Forbes
May-24-17 11:15AM  U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibbs Application for Opdivo (nivolumab) in Previously Treated Hepatocellular Carcinoma Business Wire
10:36AM  Performance of Mercks Diabetes Portfolio in 1Q17 Market Realist
May-23-17 04:27PM  With Stock Returns Of Over 205% in the Last Year, This Fund Is Proof That Hedge Funds Arent Going Anywhere Insider Monkey
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaboration agreements with Portola Pharmaceuticals, Inc., Apexigen, Inc., and Nordic Bioscience; clinical research collaborations with Array BioPharma and Novartis; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMay 14Option Exercise0.0014,551014,551Jun 08 04:51 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400180,458May 09 04:32 PM
ANDREOTTI LAMBERTODirectorApr 07Sale53.2217,000904,791935,571Apr 10 05:09 PM
ANDREOTTI LAMBERTODirectorApr 06Sale53.2917,000905,964952,571Apr 10 05:09 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554044,125Apr 04 07:17 PM
ANDREOTTI LAMBERTODirectorMar 28Sale56.2017,000955,369969,112Mar 29 06:19 PM
ANDREOTTI LAMBERTODirectorMar 27Sale56.1417,000954,451986,112Mar 29 06:19 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 17Sale56.495,000282,47021,483Mar 21 04:35 PM
Caldarella Joseph CSVP & ControllerMar 15Sale57.298,096463,77955,637Mar 22 06:20 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 14Sale56.7515,000851,22026,483Mar 16 04:37 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0087,6040199,229Mar 14 08:32 PM
Blin EmmanuelSVP, Chief Strategy OfficerMar 10Option Exercise0.0013,275023,690Mar 14 08:32 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0066,7260346,770Mar 14 08:33 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0065,4240451,862Mar 14 08:33 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,7210119,772Mar 14 08:31 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0025,592035,898Mar 14 08:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0087,3240289,293Mar 14 08:31 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.0013,696041,215Mar 14 08:30 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00102,17401,060,105Mar 14 08:30 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0031,513052,546Mar 14 08:29 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0018,799073,284Mar 14 08:29 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0033,271051,898Mar 14 08:30 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0015,484068,911Mar 14 08:29 PM
LEUNG SANDRAEVP, General CounselMar 06Sale57.0292,4055,268,563395,658Mar 07 04:39 PM
LEUNG SANDRAEVP, General CounselMar 03Option Exercise27.01116,1003,135,861488,063Mar 07 04:39 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise27.0122,598610,372212,516Mar 01 04:47 PM
Samuels Theodore R. IIDirectorFeb 27Buy56.7712,000681,24012,000Mar 01 04:47 PM
ANDREOTTI LAMBERTODirectorJan 30Option Exercise27.01100,0002,701,000957,931Feb 01 04:43 PM
Elicker John ESVP, Public Affairs & IRJan 03Option Exercise0.00950056,232Jan 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4030192,801Dec 06 04:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000187,794Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorNov 01Option Exercise22.14305,9096,772,825998,777Nov 03 05:22 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494055,505Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorOct 11Option Exercise17.51368,7066,456,042692,868Oct 13 05:00 PM
ANDREOTTI LAMBERTODirectorSep 08Sale56.9710,800615,276323,699Sep 09 04:41 PM
ANDREOTTI LAMBERTODirectorSep 07Sale56.7710,800613,116334,499Sep 09 04:41 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,596029,722Sep 07 04:33 PM
ANDREOTTI LAMBERTODirectorAug 25Sale58.9211,600683,472345,299Aug 25 05:10 PM
ANDREOTTI LAMBERTODirectorAug 24Sale59.4311,600689,359356,899Aug 25 05:10 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,511015,250Aug 03 04:56 PM
ANDREOTTI LAMBERTODirectorJul 08Sale75.0411,600870,461368,499Jul 11 05:12 PM
ANDREOTTI LAMBERTODirectorJul 07Sale73.8611,600856,776380,099Jul 11 05:12 PM
Blin EmmanuelSVP, Chief Strategy OfficerJul 02Option Exercise0.00951012,516Jul 06 05:58 PM
Cuss Francis MEVP & CSOJul 01Option Exercise0.003,6550291,628Jul 06 05:58 PM
Gordon MurdoEVP, Chief Commercial OfficerJul 01Option Exercise0.002,335014,950Jul 06 05:58 PM
ANDREOTTI LAMBERTODirectorJun 29Sale72.799,800713,342392,194Jun 30 05:42 PM
ANDREOTTI LAMBERTODirectorJun 28Sale71.6713,400960,396390,394Jun 30 05:42 PM